Phlow vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Phlow raised $37M Series C in July 2025 and holds $600M+ in government contracts including a $354M BARDA contract; manufactures critical active pharmaceutical ingredients and finished drug forms entirely within the U.S.
About
Phlow is a public benefit pharmaceutical company that develops and manufactures critical active pharmaceutical ingredients (APIs) and finished dosage forms entirely within the United States. Its mission is to strengthen national medicine supply chains by producing drugs domestically, reducing dependence on foreign API suppliers — primarily in China and India — that supply the majority of the U.S. medicine supply. Phlow''s manufacturing model uses continuous flow chemistry and advanced automation to produce APIs at lower cost and higher quality consistency than traditional batch manufacturing.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.